Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial.

Author(s): Wiesner G, Braun SL, Gruber M, Gertler R, Lange R, Tassani P, Martin K

Affiliation(s): Institute of Anaesthesiology, German Heart Centre Munich, Lazarettstr. 36, D-80636 Munich, Germany.

Publication date & source: 2011-10-03, J Antimicrob Chemother., [Epub ahead of print]

OBJECTIVES: (i) the inflammatory response to CPB may be different from that of infectious disease states that were used to establish the immunomodulatory effects of moxifloxacin; and (ii) a single intravenous dose, which was used in this investigation, may not lead to high enough plasma and intracellular concentrations.